Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Drugs From Where? | Main | Arsenic, Patents, and the World »

September 13, 2007

Don't Step Over It, Even If It's Right in Front of You

Email This Entry

Posted by Derek

There are many mistakes you can make in medicinal chemistry. Hah, I got that sentence typed out with a straight face; I wasn’t sure if I could do it or not. Mistakes! We’re up to our clavicles in them. Successful R&D is the triumph of those who manage to bungle things the least, and that doesn’t go just for the drug industry. Talk to engineers, talk to software developers. You’ll get the same perspective, accompanied by much eye-rolling and waving of arms.

And getting used to this, as I’ve noted here and there, is a psychological adjustment that a working scientist has to make. Setting your standards to a no-false-starts no-blind-alleys standard guarantees your failure, or at least ensures that you’ll be driven out of the field before have time for any success. Every working chemist knows what it’s like to put a slide of reactions together for a presentation, only to realize that they’ve just summed up months of effort in what could (theoretically, ideally) have been a few day’s work.

In med-chem, I can think of many examples where I’ve worked on a project only to recommend a compound at the end that was embarrassingly close to the starting point. Twice in a row we ended up with a compound that had one methyl group added to it compared to one of the starting compounds – mind you, those methyl groups really pulled their weight. They made a big difference in the final properties of the molecule, but we’d spent a lot of time exploring bigger changes and other regions of the molecule, none of which worked out well.

Philip Larkin, a favorite poet of mine, said that he learned from Thomas Hardy's work not to be afraid of the obvious. Like a lot of good advice, though, that’s hard to take. Researchers with an optimistic bent will wander off to new parts of the lead molecule, looking for the greener grass that they’re sure is out there. And the pessimistic ones won’t do the stuff right in front of them, either, for fear of how it’ll look. Sometimes the simple stuff gets overlooked, for no other reason that it's simple. Should that count against it?

Comments (13) + TrackBacks (0) | Category: Drug Development | Life in the Drug Labs


COMMENTS

1. John Novak on September 13, 2007 9:46 PM writes...

Talk to engineers, talk to software developers. You’ll get the same perspective, accompanied by much eye-rolling and waving of arms.

Oh, sweet Jesus, yes. In Big Engineering, that is definitely the case. We have elaborate structures in place to make sure we do not make a mistake that ends up killing someone. Then there's the structures in place to make sure we don't make a mistake that costs a few million dollars....

It is miraculous that innovation happens, sometimes.

Permalink to Comment

2. Clark Kent on September 14, 2007 7:48 AM writes...

I like to call it the "magic methyl" effect.

Permalink to Comment

3. Lars on September 14, 2007 8:04 AM writes...

I like small changes.

It's not like they're predictable...we've all seen the effects that methyl group can have on affinity when you make that ever-so-innocent move from the ortho to the meta position. Suddenly you've got a compound that's dropped 4 orders of magnitude in Ki despite your computational chemist's assurances: "There's plenty of space in that pocket!!".

But when it comes to preclinical properties, small changes often lets you get around solubility issues, metabolism, protein binding, hERG etc without opening up a whole new can of problems that you inevitably run into if you throw on a big polar extension or your favorite "big slab of fat" (a.k.a. adamantyl).

In the end, most compounds that make it really far (I'm talking Phase II/III) are actually quite pleasant to look at. Call it "minimalistic beauty". Just enough of everything you need and none of what you don't.

"Less is more" is an impotant lesson. Not just for nouveau riche basketball players on "MTV Cribs" but for medchemists too...

Permalink to Comment

4. CMC guy on September 14, 2007 10:09 AM writes...

Ah yes the wonderful life of the methyl, ethyl, butyl, futile derivatives- not sure would classify lack of enhancement as mistakes because unless it’s made and tested its hard to know if could gain improvements even with wonders of 3D modeling. Also failure of a compound in one program has been lead(s) for a different projects. You are also correct does take a certain mentality to sustain career in discovery R&D where odds are against ever finding an actual marketed drug. The best researchers I know just charge ahead and do it without long discussions on why it may or may not work. Doing Process work puts one closer to potential "drug success" and still endure the twisted pathways to solutions however the fall can be harder when a candidate fails.

I had to laugh at the retrospective insight as I do recall when writing my Thesis that felt I could have done all the work over in about 4-6 months instead of the 3.5-4 years it took (providing a labmate would stop borrowing my cleaned glass from the rack).

Permalink to Comment

5. SBC123 on September 14, 2007 10:15 AM writes...

The projects that I have been involved in had different stories. The compounds we put in animals were much different from the screening hits. I used to believe this is true for most modern drug discovery programs because the sensitive and irrelavent screening methods are picking hits far from being efficacious and PK friendly (traditional leads). Maybe I am wrong then. Half of my projects actually needed scaffold level modifications.

Permalink to Comment

6. WC on September 14, 2007 12:52 PM writes...

I've worked on several programs that have entered clinical trails and if you look at the initial leads and compare them to the final candidates, the modifications made weren't elaborate or profound, except for one of them. At a former employer, we used to have these brainstorming meetings where we were encouraged to come up with brand new leads for existing programs. Now, I'm all for new off the wall ideas, but for the most part, I came to dread these meetings. I saw way too many ideas pursued that went nowhere. I saw much more success with sticking with initial leads and keeping it as simple as possible.

Permalink to Comment

7. milkshake on September 14, 2007 10:33 PM writes...

Scaffold hopping is a worth doing if you
a) have no good lead compound - and you hope to get lucky by trying a little bit of everything
b) you have a major trouble with stability, solubility, poor selectivity or cell potency etc and you are so desperate that you think you won't be able to solve them by simple substitution changes/side-chain etc.
c)you have a good co-crystal X-ray data that gives you plenty of new ideas for dramatic improvements

The situation in point c) it treacherous because unless you have explored enough of simple modifications from the methyl-ethyl-allyl-cyclopropyl-fluoro-chloro-trifluoromethyl-methoxy category, you can end up doing big leaps of faith based on the X-ray picture, get messy and incomplete SAR and miss something important

Permalink to Comment

8. Petros on September 15, 2007 2:24 AM writes...

There were some articles about the "Magic Methyl" effect quite a while ago (15-20 years)

Permalink to Comment

9. bcpmoon on September 17, 2007 5:36 AM writes...

Ok, it was frustrating to realize that I could have done the work for my thesis in three weeks instead of years, if I had known at the beginning what I did at the end, but I found it always rewarding in itself that my end could be a beginning for somebody else, going forward into the unknown. I love science.

Permalink to Comment

10. DrSnowboard on September 17, 2007 11:40 AM writes...

Scaffold hoping (yes, the spelling is deliberate) always reminds me of that Irish joke - the one where the guy can't figure out how to give directions so he says "Well, to be honest, if you're going to Dublin / Balbriggan, I wouldn't be starting from here.."
But then again, "Little do ye know your own blessedness; for to travel hopefully is a better thing than to arrive, and the true success is to labour."

Permalink to Comment

11. xchemist on September 20, 2007 11:27 PM writes...

DrSnowboard: I understand the sentiment, but truly I would rather arrive than travel hopefully, having done both. More time then to visit with the ones one wanted to see. But the trick of it is, how can one substantially ameleiorate the problem-- efficacy and tox risk-- and still have new composition of matter to get a product? The holy grail of the med chemist; maybe it's possible, or not.

Permalink to Comment

12. MikeyMedchem on October 27, 2007 4:08 PM writes...

Does anyone have any of those references Petros mentions? They'd be very helpful to me. It's amazing that much of what we med chemists do is really based on folklore such as "magic methyl"...and we follow these premises by word of mouth instead of actually seeing the research!

Permalink to Comment

13. milkshake on October 28, 2007 3:15 PM writes...

Look up the potency of cis-3-methyl fentanyl vs the plain olf fentanyl, there is >20 potency improvement with the (-) cis enantiomer. It is about 1 thousand times more potent then heroin. (Fentanyl is only 50 times more potent). Racemic cis 3-methyl fentanyl was used in the Nord-Ost theatre siege in Moscow. Since no antidote was administered to the hostages, more than 100 of them died of overdose. (The OMON troops had the antidote for their own use - but were not allowed to say that Naloxone/Naltrexone would work because it was such a secret).

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
One and Done
The Latest Protein-Protein Compounds
Professor Fukuyama's Solvent Peaks
Novartis Gets Out of RNAi
Total Synthesis in Flow
Sweet Reason Lands On Its Face
More on the Science Chemogenomic Signatures Paper
Biology Maybe Right, Chemistry Ridiculously Wrong